The annual New York International Automobile Show (NYIAS) takes over the Jacob Javits Center in Manhattan from March 30th – April 8th. For over 100 years NYIAS has showcased some of the hottest cars and trucks ever seen -- all under one roof. Micah Muzio puts viewers on the inside track at the show with advance looks at the brand-new models and more concept vehicles than ever before! These cutting-edge vehicles will provide a glimpse into the future of automobile design and technology.
To view the multimedia release go to:
https://www.multivu.com/players/English/82580241-new-york-international-auto-show-nyias-chrysler-genesis-hyundai/
Schick Hydro announced today the next step in its quest to foster innovation by spotlighting and investing in a community that continues to transform the industry – independent game developers. The brand’s efforts include a new, fan-choice award for The Game Awards 2017 (“The Best Debut Indie Game – Presented by Schick Hydro”), a consumer giveaway that puts break-out indie games in fans’ hands, an exclusive indie game jam in partnership with Playcrafting and a custom arcade experience at The Game Awards.
“From the launch of the Schick Hydro 3 to the evolution of Schick Hydro 5, Schick Hydro is a challenger brand that’s constantly evolving to enhance the men’s grooming experience and bring innovation to the category,” said Anastasia Tobias, Senior Brand Manager of Schick Hydro at Edgewell Personal Care. “Innovation is about challenging the status quo to create something that enhances people’s lives. As innovators, it’s important that we support other innovators, which is why we’re extending our mission to “protect and defend” to indie game developers – creating opportunities for these rising-stars to continue to hone their craft and advance their industry.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8232951-schick-hydro-the-game-awards/
Kia Motors America (KMA) transforms dreams into reality at the 2017 Specialty Equipment Market Association (SEMA) Show with custom vehicle builds and opportunities to experience the all-new Stinger GT. Attendees will have the opportunity to ride alongside professional Formula Drift drivers who will provide thrilling drifting demonstrations as well as experience the vehicle’s athletic performance first hand from behind the wheel on a challenging autocross course2. In advance of the Stinger going on sale this December,3 KMA invited West Coast Customs to modify and feature two highly customized works of art, one based on the Stinger GT and the other on the current Cadenza premium sedan. KMA also revealed a uniquely modified Stinger equipped with a host of parts and accessories from leading aftermarket suppliers.
“We are so thrilled to show off what Kia has become at SEMA because 2017 is a momentous year for our Kia brand,” said Justin Sohn, President and CEO of Kia Motors America. “We ranked #1 in quality for the second year in a row in JD Power’s Initial Quality Study, we are top three in Consumer Reports reliability and we are now introducing the all-new 2018 four-door Stinger Sports Fastback, Kia’s fastest ever and our first performance vehicle.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8016956-kia-motors-2017-sema-show/
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8121952-st-jude-childrens-childhood-solid-tumor-network/
23andMe, working in collaboration with the Milken Institute and Lundbeck, today announced that they have commenced enrollment for a first-of-its kind genetic study designed to gain understanding of the underlying biology of major depressive and bipolar disorders. This study will combine cognitive assessments with genetic data and survey responses to assess how genes influence brain processes – such as attention, decision-making and visual perception – in individuals who live with these serious mental health conditions.
“We know genetics play a role in the development of depression and bipolar, however there is a long pathway from our genes to the manifestation of complex diseases like these,” said Emily Drabant Conley, PhD., Vice President of Business Development at 23andMe. “We need to look at these conditions in a more comprehensive way to advance our understanding. By studying cognitive function alongside genetics and other environmental variables on a massive scale, we hope to take a significant step forward in the study of depression and bipolar.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8150951-23andme-genetic-study-depression-bipolar-disorders/
Today on Rare Disease Day, My Life, Our Future, a national program founded by leaders in the bleeding disorder community, including Bloodworks Northwest, the American Thrombosis and Hemostasis Network, the National Hemophilia Foundation and Bioverativ Inc., opened the largest research repository of its kind in the world to scientists. The My Life, Our Future Research Repository is a collection of genetic data and blood samples that are linked to phenotypic data from more than 5,000 people in the U.S. with hemophilia, a rare disorder that impairs the ability of one’s blood to clot. The My Life, Our Future Research Repository will allow researchers to advance the scientific understanding of the disorder, including genetic differences that affect bleeding severity and reaction to certain treatments.
To view the multimedia release go to:
https://www.multivu.com/players/English/8046151-national-hemophilia-foundation-my-life-our-future/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide.
This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
Ascensia Diabetes Care today announced the availability of the CONTOUR®NEXT ONE blood glucose monitoring system (BGMS) in the United Kingdom, one of the next steps in the evolution of self-monitoring of blood glucose. As part of the system, the CONTOUR®NEXT ONE meter and CONTOUR®DIABETES app seamlessly connect, which makes capturing blood glucose results effortless for people with diabetes. The system enables patterns and trends to be revealed that can help people understand their diabetes, and may help to improve diabetes management.
The system features an easy-to-use wireless-enabled smart meter that links to a smart mobile device via Bluetooth® connectivity. The CONTOUR®NEXT ONE meter gives immediate feedback and also seamlessly connects to the CONTOUR®DIABETES app, which collects, stores and analyses patient blood glucose results received from the meter. The app combines these results with other data recorded by the user, to provide detailed information about their condition that can help them understand how their everyday lives may impact their blood glucose readings, including alerts for critical high or critical low readings. Through the app, meter users can also share with their healthcare professional the reports of their blood glucose results and patterns, either in advance or on the day of their appointment, helping to create more informed discussions.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7954951-contour-next-one-bgms-ascensia/
Team In Training. Light The Night. Man & Woman of the Year. Student Series. Leukemia Cup Regatta. More than 13 million participants in these popular fundraising campaigns last year alone helped The Leukemia & Lymphoma Society (LLS) invest more than $1 billion in research to advance lifesaving treatments and cures for blood cancer patients.
For Blood Cancer Awareness Month this September, LLS is reminding us that despite progress, much work still needs to be done to save more lives. More than 1.2 million people in the U.S. are living with or in remission from a blood cancer. Leukemia causes more deaths than any other cancer among children, adolescents and adults younger than 20 years. Leukemia, lymphoma and myeloma are expected to cause the deaths of an estimated 58,320 people in the U.S. in 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554853-lls-blood-cancer-awareness-month/
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine.
Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season.
“Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
Today, Chick-fil-A® launches Chick-fil-A One ™ – a mobile app that gives customers a new way to experience Chick-fil-A. The app is designed to give customers more choices to better meet their needs, including the ability to customize their meal, order and pay in advance and skip the line at the register, speeding up the process of waiting at the counter or drive-thru.
According to a recent survey commissioned by Chick-fil-A, 82 percent of millennial parents say they would do almost anything to avoid long lines at fast food restaurants when they are with their children. In fact, nearly half (48 percent) said they would rather not eat at all than stand in a line.
To view the multimedia release go to:
http://www.multivu.com/players/English/7764751-chick-fil-a-one-app/
Volvo Cars is teaming up with footballing icon Zlatan Ibrahimović again for the European launch campaign of the V90 premium estate in advance of the European Championships football tournament. The campaign will go live tonight on national TV stations and on Social Media platforms.
The new campaign shows the former Paris Saint-Germain striker, a long-time Volvo driver and fan, looking back at his rise from humble beginnings in one of Sweden’s toughest neighbourhoods in Malmö to international sporting stardom.
Zlatan, who is currently preparing for the European Championships feels a close affinity with the Swedish car brand.
“I’m happy to be working with Volvo Cars again. I’ve seen the new cars, I’ve driven and tested them. And I think they’re fantastic. Just like me, Volvo has gone their own way and dared to think differently. The previous campaign we did was good, but this time it’s Made by Zlatan,” said Zlatan Ibrahimović.
“The campaign is a celebration of the independent mind, of the power that lies in the ability to think differently. There are many similarities between Zlatan’s and Volvo’s journeys. We haven’t gotten to where we are now by doing the same as everyone else,” said Anders Gustafsson, Senior Vice President, Europe, Middle East and Africa at Volvo Car Group.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7848551-volvo-cars-v90-campaign-zlatan-ibrahimovic/
